Core Viewpoint - The announcement highlights the promising results of the small molecule GLP-1R agonist ASC30, which is being developed for weight maintenance therapy, showing a long apparent half-life of 75 days in obese subjects during a Phase Ib clinical trial [1] Group 1: Clinical Trial Results - ASC30 demonstrated an apparent half-life of 75 days in obese subjects, indicating its potential for long-term weight management [1] - After a single subcutaneous injection of 100 mg ASC30, the time to reach peak blood concentration (Cmax) was 17 days post-administration [1] - The blood concentration of ASC30 decreased to 50% of Cmax approximately 75 days after administration, supporting its quarterly dosing regimen [1] Group 2: Drug Development Potential - ASC30 is noted as the fastest progressing quarterly administered incretin drug in clinical development, suggesting a competitive edge in the market for weight management therapies [1] - The good tolerability of ASC30 supports its potential as a long-term maintenance therapy for weight management [1]
歌礼制药-B：小分子GLP-1R激动剂ASC30在肥胖受试者中显示出75天的表观半衰期